Novavax COVID Vaccine Approaches Full FDA Approval in the United States
Novavax's COVID-19 vaccine is moving closer to achieving full approval from the U.S. Food and Drug Administration (FDA), according to statements made by the company on April 25, 2025. This development has positively impacted Novavax's stock, which surged over 21% in early trading, and is seen as a significant step in the vaccine's journey beyond emergency use authorization.
Currently, Novavax's vaccine remains available in the U.S. under emergency use authorization (EUA), differing from the Pfizer and Moderna vaccines, which have obtained full FDA approval for specific age groups. The company disclosed that the FDA has requested additional clinical data from recipients of the vaccine as part of the approval process. In response, Novavax has stated it is engaging with the FDA expeditiously to obtain full approval as soon as possible.
Securing full FDA approval is a critical step because it allows the vaccine to remain on the market even after the end of the public health emergency—something that is particularly relevant now that the World Health Organization declared an end to COVID-19's global emergency in May 2023. During the initial approval phase, the process was halted in April, leading to speculations about possible influences, including recent political figures and internal disagreements within the FDA regarding vaccine safety.
Unlike mRNA vaccines from Pfizer and Moderna, which use genetic material to instruct cells to produce the spike protein, Novavax's vaccine employs lab-grown copies of the spike protein combined with an immune-boosting agent. This protein-based approach offers an alternative method for training the immune system against COVID-19 and is the only one of its kind currently available in the U.S.
Given the ongoing need to adapt to new virus variants, vaccine manufacturers routinely update their COVID-19 shots annually, similar to flu vaccines, to enhance protection. As Novavax progresses towards full FDA approval, it signifies a continued effort to expand vaccine options and bolster COVID-19 defenses in the United States.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Enhancing Prenatal Care to Reduce Low Birth Weight Risks
A new study highlights the critical role of increased prenatal checkups in improving birth weights and reducing low birth weight cases in The Gambia, supporting better neonatal health outcomes.
Collaborative Experience Between Surgeons and Anesthesiologists Reduces Patient Complications
Research shows that prior collaborative experience between surgeons and anesthesiologists is linked to fewer postoperative complications, emphasizing the value of team stability in high-risk surgeries.
Recognizing the Hidden Signs of Androgen Excess in Women
Many women with excess androgens experience symptoms like acne, hair loss, and irregular periods, often dismissed as cosmetic. Early diagnosis and holistic care are vital for better health outcomes.
Understanding Tuberculosis as It Emerges in Maine and North Carolina: Who Is at Risk?
Recent reports of tuberculosis in Maine, North Carolina, and California highlight the importance of awareness, early detection, and treatment of this bacterial disease that remains a public health challenge in the U.S.